Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

Inclusion Criteria: * Histologically proven localized prostate carcinoma diagnosed using prostate biopsy showing: * Gleason 3+3 prostate * Gleason 3+4 prostate adenocarcinoma is acceptable provided it is not present in more than 2 cores and no more than 50% cancer in any core. * Clinical stage up to cT2a - N0/Nx - M0/Mx. * Serum prostate-specific antigen (PSA) ˂ 20ng/ml * Prostate volume ≥ 25 cc and ≤ 70 cc. * Male subjects aged 18 years or older. * Signed Informed Consent Form by the patient. Exclusion Criteria: * Unwillingness to accept the treatment. * Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy)or chemotherapy. * Any surgical intervention for benign prostatic hypertrophy. * Any condition or history of illness or surgery that may pose an additional risk to men undergoing the VTP procedure. * Life expectancy less than 10 years. * Participation in another clinical study involving an investigational product within 1 month before study entry. * Subject unable to understand the patient's informed consent document, to give consent voluntarily or to complete the study tasks, especially unable to understand and fulfill the health-related QoL questionnaire. * Subject in custody and or in residence in a nursing home or rehabilitation facility. * Any condition or history of active rectal inflammatory bowel disease or other factors which may increase the risk of fistula formation; * Any hormonal manipulation (excluding 5-alpha-reductase inhibitors) that alters androgen production or use of androgen supplements within the previous 6 months; * Any history of urethral stricture disease; * Any history of acute urinary retention within 6 months of study entry